Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RET fusion||differentiated thyroid gland carcinoma||sensitive||Selpercatinib||Guideline||Actionable||Retevmo (selpercatinib) is included in guidelines for patients with advanced or metastatic differentiated thyroid gland carcinoma harboring RET fusions (PMID: 31549998, PMID: 35491008; ESMO.org).||35491008 31549998 detail...|
|PubMed Id||Reference Title||Details|
|ESMO Clinical Practice Guidelines||Full reference...|
|(35491008)||ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.||Full reference...|
|(31549998)||Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.||Full reference...|